Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(9):814–820. doi: 10.1111/j.1349-7006.2003.tb01524.x

Mirimostim (macrophage colony‐stimulating factor; M‐CSF) improves chemotherapy‐induced impaired natural killer cell activity, Th1/Th2 balance, and granulocyte function

Takao Hidaka 1, Shinobu Akada 2, Akiko Teranishi 3, Hajime Morikawa 3, Shinji Sato 4, Yuji Yoshida 4, Akira Yajima 4, Nobuo Yaegashi 4, Kunihiro Okamura 4, Shigeru Saito 1,✉
PMCID: PMC11160279  PMID: 12967481

Abstract

The purpose of this study was to clarify the effects of mirimostim (macrophage colony‐stimulating factor; M‐CSF) on immunological functions after chemotherapy. The percentage of natural killer (NK) cells in peripheral blood mononuclear cells (PBMCs), NK cell activity, T‐helper cell 1/T‐helper cell 2 (Th1/Th2) ratio, and superoxide anion production by granulocytes (granulocyte function) were measured as immunological parameters before and after chemotherapy in 44 patients with primary ovarian cancer who received at least three consecutive courses of postoperative chemotherapy. Patients were observed during the first course of chemotherapy, and 39 patients who presented grade III or IV neutropenia were entered into this study and randomly allocated to an M‐CSF‐administered group (group 1; 19 patients) and a non‐M‐CSF‐administered group (group 2; 20 patients) for the second course. For the third course, a crossover trial was conducted. In the observation period, chemotherapy significantly impaired the immunological parameters. In particular, those parameters were significantly decreased at day 14 compared to the level before chemotherapy. The values of the parameters of group 1 were significantly higher than those of group 2. In the course of chemotherapy during which M‐CSF was administered, 19 of the 39 patients presented grade IV neutropenia, and received granulocyte colony‐stimulating factor (G‐CSF) between days 7 and 14. We compared the changes of those immunological parameters in the M‐CSF alone group and the M‐CSF+G‐CSF group, and found that the concomitant use of G‐CSF did not further improve the parameters. These results indicate that chemotherapy markedly impaired the immunological functions, and that the administration of M‐CSF significantly improved the impaired immunological functions.

References

  • 1. Hibi S, Yoshihara T, Nakajima F, Misu H, Mabuchi O, Imashuku S. Effect of recombinant human granulocyte‐colony stimulating factor (rhG‐CSF) on immune system in pediatric patients with a plastic anemia. Pediatr Hematol Oncol 1994; 11: 319–23. [DOI] [PubMed] [Google Scholar]
  • 2. Miller JS, Prosper F, McCullar V. Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony‐stimulating factor‐mobilized peripheral blood progenitor cell collections. Blood 1997; 15: 3098–105. [PubMed] [Google Scholar]
  • 3. Rondelli D, Raspadori D, Anasetti C, Bandini G, Re F, Arpinati M, Stanzani M, Morelli A, Baccini C, Zaccaria A, Lemoli RM, Tura S. Alloantigen presenting capacity, T cell alloreactivity and NK function of G‐CSF‐mobilized peripheral blood cells. Bone Marrow Transplant 1998; 22: 631–7. [DOI] [PubMed] [Google Scholar]
  • 4. Klangsinsirikul P, Russell NH. Peripheral blood stem cell harvests from G‐CSF‐stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol 2002; 30: 495–501. [DOI] [PubMed] [Google Scholar]
  • 5. Valente JF, Alexander JW, Li BG, Noel JG, Custer DA, Ogle JD, Ogle CK. Effect of in vivo infusion of granulocyte colony‐stimulating factor on immune function. Shock 2002; 17: 23–9. [DOI] [PubMed] [Google Scholar]
  • 6. Mukai M, Bohgaki T, Kondo M, Notoya A, Kohno M. Changes in the T‐helper cell 1 /T‐helper cell 2 balance of peripheral T‐helper cells after autologous peripheral blood stem cell transplantation for non‐Hodgkin's lymphoma. Ann Hematol 2001; 80: 715–21. [DOI] [PubMed] [Google Scholar]
  • 7. Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S, Aversa F, Tabilio A, Romani L, Martelli MF, Velardi A. Postgrafting administration of granulocyte colony‐stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype‐mismatched hematopoietic transplants. Blood 2001; 97: 2514–21. [DOI] [PubMed] [Google Scholar]
  • 8. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte‐colony stimulating factor mobilizes T helper 2‐inducing dendritic cells. Blood 2000; 95: 2484–90. [PubMed] [Google Scholar]
  • 9. Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J, Young NS. Pharmacologic doses of granulocyte colony‐stimulating factor affect cytokine production by lymphocytes in vitro and in vivo . Blood 2000; 95: 2269–74. [PubMed] [Google Scholar]
  • 10. Durek C, Schafer I, Braasch H, Ulmer AJ, Ernst M, Flad HD, Jocham D, Bohle A. Effects of colony‐stimulating factors on cellular cytotoxicity. Cancer Immunol Immunother 1997; 44: 35–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Baxevanis CN, Tsavaris NB, Papadhimitriou SI, Zarkadis IK, Papadopoulos NG, Bastounis EA, Papamichail M. Granulocyte‐macrophage colony‐stimulating factor improves immunological paramaters in patients with refractory solid tumors receiving second‐line chemotherapy: correlation with clinical responses. Eur J Cancer 1997; 33: 1202–8. [DOI] [PubMed] [Google Scholar]
  • 12. Teranishi A, Akada S, Saito S, Hatake K, Morikawa H. Macrophage colony‐stimulating factor restored chemotherapy‐induced granulocyte dysfanctions role of IL‐8 production by monocyte. Int Immunopharmacol 2002; 2: 83–94. [DOI] [PubMed] [Google Scholar]
  • 13. Motoyoshi K. Biological activities and clinical application of M‐CSF. Int J Hematol 1998; 67: 109–22. [DOI] [PubMed] [Google Scholar]
  • 14. Ohno R, Miyawaki S, Hatake K, Kuriyama K, Saito K, Kanamaru A, Kobayashi T, Kodera Y, Nishikawa K, Matsuda S, Yamada O, Omoto E, Takeyama H, Tsukuda K, Asou N, Tanimoto M, Shiozaki H, Tomonaga M, Masaoka T, Miura Y, Takaku F, Ohashi Y, Motoyoshi K. Human urinary macrophage colony‐stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double‐blind controlled study. J Clin Oncol 1997; 15: 2954–65. [DOI] [PubMed] [Google Scholar]
  • 15. Hidaka T, Fujimura M, Nakashima A, Higuma S, Yamagishi N, Tsuda H, Sakai M, Saito S. Macrophage colony‐stimulating factor (M‐CSF) prevents infectious death induced by chemotherapy in mice, while granulocyte‐CSF does not. Jpn J Cancer Res 2002; 93: 426–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Mizutani K, Takeuchi S, Ohashi Y, Yakushiji M, Nishimura H, Takahashi T, Maruhashi T, Ueda K, Noda K, Watanabe Y, Kawana T, Terashima Y, Ochiai K, Goto S, Takaku F, Motoyoshi K. Clinical usefulness of macrophage colony‐stimulating factor for ovarian cancers: long‐term prognosis after five years. Oncol Rep 2003; 10: 127–31. [PubMed] [Google Scholar]
  • 17. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcR‐positive and negative killer cells. J Immunol 1989; 143: 3183–91. [PubMed] [Google Scholar]
  • 18. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulation of human natural killer cells defined by expression of the leu‐7(HNK‐1) and Leu(NK15) antigen. J Immunol 1983; 131: 1789–96. [PubMed] [Google Scholar]
  • 19. Prussin C, Metcalf D. Detection of intracytoplasmic cytokine using flow cytometry and direct conjugated anti‐cytokine antibodies. Immunol Meth 1995; 188: 117–28. [DOI] [PubMed] [Google Scholar]
  • 20. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils A graded response to membrane stimulation. J Immunol 1983; 130: 1910–7. [PubMed] [Google Scholar]
  • 21. Bass DA, Dechatelet LR, McCall CE. Independent stimulation of motility and the oxidative metabolic burst of human polymorphonuclear leukocytes. J Immunol 1978; 121: 172–8. [PubMed] [Google Scholar]
  • 22. Hidaka T, Fujimura M, Sakai M, Saito S. Macrophage colony‐stimulating factor prevents febrile neutropenia induced by chemotherapy. Jpn J Cancer Res 2001; 92: 1251–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Nemunaitis J, Shannon‐Dorcy K, Appelbaum FR, Meyers J, Owens A, Day R, Ando D, O'Neill C, Buckner D, Singer J. Long‐term follow‐up of patients with invasive fungal disease who received adjunctive with recombinant human macrophage colony‐stimulating factor. Blood 1993; 82: 1422–7. [PubMed] [Google Scholar]
  • 24. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factor: biology and clinical application. N Engl J Med 1989; 321: 1449–59. [DOI] [PubMed] [Google Scholar]
  • 25. Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, Layton JE, Green MD, Souza L, Fox RM. Granulocyte colony‐stimulating factor and neutrophil recovey after high‐dose chemotherapy and autologus bone marrow transplantation. Lancet 1989; ii: 891–5. [DOI] [PubMed] [Google Scholar]
  • 26. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A. A randomized, double‐blind, placebo‐controlled, phase I study of filgrastim in remission induction and consolidation therapy for adults with de novo myeloid leukemia. Blood 1997; 90: 4710–8. [PubMed] [Google Scholar]
  • 27. Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, Synold T, Relling MV, Ribeiro RC, Crist WM, Evans WE. Human granulocyte colony‐stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336: 1781–7. [DOI] [PubMed] [Google Scholar]
  • 28. Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, Levitt R, Suman VJ, Witzig TE, Wieand HS, Miller LL, Moertel CG. Granulocyte colony‐stimulating factor in severe chemotherapy‐induced febrile neutropenia. N Engl J Med 1997; 336: 1776–80. [DOI] [PubMed] [Google Scholar]
  • 29. Sakurai T, Misawa E, Yamada M, Hayasawa H, Motoyoshi K. Effects of macrophage colony‐stimulating factor on cyclophosphamide‐injected mouse NK 1.1+ cell activity. Cancer Immunol Immunother. 2000; 49: 94–100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Sakurai T, Wakimoto N, Yamada M, Shimamura S, Motoyoshi K. Effects of macrophage colony‐stimulating factor on mouse NK 1.1+ cell activity in vivo . Int J Immunopharmacol 1998; 20: 401–13. [DOI] [PubMed] [Google Scholar]
  • 31. Misawa E, Sakurai T, Yamada M, Hayasawa H, Motoyoshi K. Effects of macrophage colony‐stimulating factor and interleukin‐2 administration on NK1.1(+) cells in mice. Int J Immunopharmacol 2000; 22: 967–77. [DOI] [PubMed] [Google Scholar]
  • 32. Garzetti GG, Ciavattini A, Muzzioli M, Romanini C. Cisplatin‐based poly chemotherapy reduces natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin‐12 incubation. Cancer 1999; 15: 2226–31. [DOI] [PubMed] [Google Scholar]
  • 33. Suzuki M, Ohwada M, Shimizu Y, Yamada M, Sato I. An open‐label, randomized trial, of the effects of macrophage versus granulocyte colony‐stimulating factor on natural killer cell activity, lymphokine activated killer cell activity, interleukin‐2 production, and leukocyte count in patients after chemotherapy for ovarian cancer. Curr Ther Res 1997; 58: 698–705. [Google Scholar]
  • 34. Martinez C, Urbano‐Ispizua A, Rozman C, Marin P, Mazzara R, Carreras E, Rovira M, Sierra J, Briones J, Ordinas A, Montserrat E. Effects of G‐CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. Ann Hematol 1996; 72: 269–72. [DOI] [PubMed] [Google Scholar]
  • 35. Sica S, Rutella S, Di Mario A, Salutari P, Rumi C, Ortu la Barbera E, Etuk B, Menichella G, D'Onofrio G, Leone G. RhG‐CSF in healthy donors: mobilization of peripheral hemopoietic progenitors and effect on peripheral blood leukocytes. J Hemotother 1996; 54: 391–7. [DOI] [PubMed] [Google Scholar]
  • 36. Trinchieri G. Interleukin‐12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70: 83–243. [DOI] [PubMed] [Google Scholar]
  • 37. Tadokoro CE, de Almeida Abrahamsohn I. Bone marrow‐derived macro‐phages grown in GM‐CSF or M‐CSF differ in their ability to produce IL‐12 and to induce IFN‐gamma production after stimulation with Trypanosoma cruzi antigens. Immunol Lett 2001; 77: 31–8. [DOI] [PubMed] [Google Scholar]
  • 38. Detmers PA, Lo SK, Olsen‐Egbert E, Walz A, Baggiolini M, Cohn ZA. Neutrophil‐activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J Exp Med 1990; 171: 1155–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Hashimoto S, Yoda M, Yamada M, Yanai N, Kawashima T, Motoyoshi K. Macrophage colony‐stimulating factor induces interleukin‐8 production in human monocytes. Exp Hematol 1996; 24: 123–8. [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES